TRADES
Latest Trades
4442
results found
FUND
DATE
ACTION
TICKER
COMPANY
SHARES
% of ETF
ARKG 6 Jun 2023 Buy ADPT ADAPTIVE BIOTECHNOLOGIES 15,129 0.0054
ARKG 5 Jun 2023 Sell SDGR SCHRODINGER INC 21,712 0.0390
ARKG 5 Jun 2023 Buy NTLA INTELLIA THERAPEUTICS INC 5,906 0.0115
ARKG 5 Jun 2023 Sell EXAS EXACT SCIENCES CORP 7,106 0.0283
ARKG 5 Jun 2023 Buy DNA GINKGO BIOWORKS HOLDINGS INC 50,054 0.0037
ARKG 5 Jun 2023 Sell CRSP CRISPR THERAPEUTICS AG 5,159 0.0158
ARKG 5 Jun 2023 Buy CERS CERUS CORP 124,449 0.0131
ARKG 5 Jun 2023 Buy ADPT ADAPTIVE BIOTECHNOLOGIES 115,016 0.0408
ARKG 2 Jun 2023 Sell SDGR SCHRODINGER INC 14,810 0.0255
ARKG 2 Jun 2023 Sell EXAS EXACT SCIENCES CORP 6,039 0.0245
ARKG 2 Jun 2023 Buy DNA GINKGO BIOWORKS HOLDINGS INC 205,819 0.0155
ARKG 2 Jun 2023 Buy ADPT ADAPTIVE BIOTECHNOLOGIES 79,853 0.0277
ARKG 1 Jun 2023 Sell SDGR SCHRODINGER INC 77,359 0.1302
ARKG 1 Jun 2023 Buy PRME PRIME MEDICINE INC 1,120 0.0007
ARKG 1 Jun 2023 Buy ADPT ADAPTIVE BIOTECHNOLOGIES 81,438 0.0279
ARKG 31 May 2023 Sell SDGR SCHRODINGER INC 35,869 0.0608
ARKG 31 May 2023 Buy PRME PRIME MEDICINE INC 7,406 0.0049
ARKG 31 May 2023 Buy ADPT ADAPTIVE BIOTECHNOLOGIES 233,144 0.0790
ARKG 30 May 2023 Sell SDGR SCHRODINGER INC 20,165 0.0362
ARKG 30 May 2023 Buy PRME PRIME MEDICINE INC 19,363 0.0128
ARKG 30 May 2023 Buy ADPT ADAPTIVE BIOTECHNOLOGIES 109,277 0.0373
ARKG 26 May 2023 Sell SDGR SCHRODINGER INC 29,485 0.0526
ARKG 26 May 2023 Buy PATH UIPATH INC 9,648 0.0072
ARKG 26 May 2023 Buy ADPT ADAPTIVE BIOTECHNOLOGIES 33,099 0.0111
ARKG 25 May 2023 Sell SDGR SCHRODINGER INC 7,488 0.0136
ARKG 25 May 2023 Buy PRME PRIME MEDICINE INC 15,532 0.0099
ARKG 25 May 2023 Buy PATH UIPATH INC 715,623 0.4920
ARKG 25 May 2023 Sell NVDA NVIDIA CORP 26,755 0.4925
ARKG 25 May 2023 Sell EXAS EXACT SCIENCES CORP 8,540 0.0336
ARKG 25 May 2023 Buy ADPT ADAPTIVE BIOTECHNOLOGIES 304,237 0.1001
ARKG 24 May 2023 Sell SDGR SCHRODINGER INC 58,584 0.1047
ARKG 24 May 2023 Buy PRME PRIME MEDICINE INC 61,730 0.0399
ARKG 24 May 2023 Sell EXAS EXACT SCIENCES CORP 10,263 0.0407
ARKG 24 May 2023 Buy ADPT ADAPTIVE BIOTECHNOLOGIES 100,011 0.0316
ARKG 23 May 2023 Sell EXAS EXACT SCIENCES CORP 28,203 0.1114
ARKG 22 May 2023 Buy PRME PRIME MEDICINE INC 799 0.0005
ARKG 22 May 2023 Sell EXAS EXACT SCIENCES CORP 9,981 0.0424
ARKG 15 May 2023 Buy MASS 908 DEVICES INC 90,675 0.0354
ARKG 12 May 2023 Buy NVTA INVITAE CORP 1,748 0.0001
ARKG 12 May 2023 Buy MASS 908 DEVICES INC 25,349 0.0098
ARKG 12 May 2023 Buy ADPT ADAPTIVE BIOTECHNOLOGIES 77,311 0.0261
ARKG 11 May 2023 Buy NVTA INVITAE CORP 80,287 0.0059
ARKG 11 May 2023 Buy MASS 908 DEVICES INC 24,733 0.0097
ARKG 11 May 2023 Sell INCY INCYTE CORP 62,110 0.2070
ARKG 11 May 2023 Sell EXAS EXACT SCIENCES CORP 26,192 0.1065
ARKG 11 May 2023 Buy DNA GINKGO BIOWORKS HOLDINGS INC 704,208 0.0484
ARKG 11 May 2023 Buy CDNA CAREDX INC 110,667 0.0481
ARKG 11 May 2023 Buy ADPT ADAPTIVE BIOTECHNOLOGIES 330,423 0.1185
ARKG 10 May 2023 Buy RXRX RECURSION PHARMACEUTICALS 147,832 0.0424
ARKG 10 May 2023 Buy PRME PRIME MEDICINE INC 22,198 0.0162
ARKG 10 May 2023 Buy NVTA INVITAE CORP 46,094 0.0034
ARKG 10 May 2023 Buy MASS 908 DEVICES INC 3,395 0.0013
ARKG 10 May 2023 Sell INCY INCYTE CORP 10,945 0.0367
ARKG 10 May 2023 Buy ADPT ADAPTIVE BIOTECHNOLOGIES CORP 85,741 0.0317
ARKG 9 May 2023 Buy RXRX RECURSION PHARMACEUTICALS 189,682 0.0554
ARKG 9 May 2023 Buy PRME PRIME MEDICINE INC 242,093 0.1810
ARKG 9 May 2023 Sell IONS IONIS PHARMACEUTICALS INC 99,146 0.1844
ARKG 9 May 2023 Sell INCY INCYTE CORP 13,354 0.0463
ARKG 9 May 2023 Sell EXAS EXACT SCIENCES CORP 16,236 0.0592
ARKG 9 May 2023 Buy ADPT ADAPTIVE BIOTECHNOLOGIES 42,051 0.0147
ARKG 8 May 2023 Buy RXRX RECURSION PHARMACEUTICALS 188,297 0.0548
ARKG 8 May 2023 Buy PRME PRIME MEDICINE INC 4,886 0.0037
ARKG 8 May 2023 Sell IONS IONIS PHARMACEUTICALS INC 10,396 0.0196
ARKG 8 May 2023 Sell INCY INCYTE CORP 25,884 0.0906
ARKG 8 May 2023 Buy BEAM BEAM THERAPEUTICS INC 852 0.0015
ARKG 8 May 2023 Buy ADPT ADAPTIVE BIOTECHNOLOGIES 99,981 0.0340
ARKG 5 May 2023 Buy TWST TWIST BIOSCIENCE CORP 20,523 0.0144
ARKG 5 May 2023 Buy SDGR SCHRODINGER INC 175,735 0.2539
ARKG 5 May 2023 Buy PACB PACIFIC BIOSCIENCES OF CALIF 14,921 0.0094
ARKG 5 May 2023 Sell INCY INCYTE CORP 76,658 0.2723
ARKG 4 May 2023 Buy PACB PACIFIC BIOSCIENCES OF CALIF 23,848 0.0152
ARKG 4 May 2023 Sell INCY INCYTE CORP 5,316 0.0193
ARKG 3 May 2023 Buy PACB PACIFIC BIOSCIENCES OF CALIF 124,862 0.0812
ARKG 3 May 2023 Buy NVTA INVITAE CORP 16,353 0.0012
ARKG 3 May 2023 Sell INCY INCYTE CORP 20,392 0.0775
ARKG 2 May 2023 Buy TDOC TELADOC INC 19,605 0.0276
ARKG 2 May 2023 Buy PSNL PERSONALIS INC 90,849 0.0111
ARKG 2 May 2023 Buy PRME PRIME MEDICINE INC 1,061 0.0008
ARKG 2 May 2023 Buy NVTA INVITAE CORP 198,715 0.0141
ARKG 2 May 2023 Buy NTLA INTELLIA THERAPEUTICS INC 10,697 0.0210
ARKG 2 May 2023 Buy BEAM BEAM THERAPEUTICS INC 7,083 0.0113
ARKG 1 May 2023 Buy TDOC TELADOC INC 26,492 0.0376
ARKG 1 May 2023 Buy PSNL PERSONALIS INC 14,638 0.0018
ARKG 1 May 2023 Buy NVTA INVITAE CORP 1,285 0.0001
ARKG 1 May 2023 Buy BEAM BEAM THERAPEUTICS INC 788 0.0013
ARKG 28 Apr 2023 Buy TDOC TELADOC INC 26,225 0.0374
ARKG 28 Apr 2023 Buy PSNL PERSONALIS INC 80,334 0.0099
ARKG 28 Apr 2023 Buy NTLA INTELLIA THERAPEUTICS INC 67 0.0001
ARKG 28 Apr 2023 Sell EXAS EXACT SCIENCES CORP 77,196 0.2651
ARKG 28 Apr 2023 Buy BEAM BEAM THERAPEUTICS INC 798 0.0013
ARKG 28 Apr 2023 Buy ACCD ACCOLADE INC 173,997 0.1238
ARKG 27 Apr 2023 Buy NTLA INTELLIA THERAPEUTICS INC 4,217 0.0081
ARKG 27 Apr 2023 Sell EXAS EXACT SCIENCES CORP 21,168 0.0716
ARKG 27 Apr 2023 Buy BEAM BEAM THERAPEUTICS INC 6,971 0.0114
ARKG 26 Apr 2023 Sell TXG 10X GENOMICS INC 14,240 0.0388
ARKG 26 Apr 2023 Buy PRME PRIME MEDICINE INC 1,928 0.0013
ARKG 26 Apr 2023 Buy NVTA INVITAE CORP 39,744 0.0026
ARKG 26 Apr 2023 Buy NTLA INTELLIA THERAPEUTICS INC 16,992 0.0324
ARKG 26 Apr 2023 Sell EXAS EXACT SCIENCES CORP 23,767 0.0790
ARKG 26 Apr 2023 Buy BEAM BEAM THERAPEUTICS INC 24,041 0.0386
Latest Blogs
ARK by Cathie Wood is still suffering a year after its apex.

Cathie Wood's flagship exchange-traded fund hit an all-time high in February of this year. Her preferred disruptive-tech chasing strategy may still be in for a lot of suffering after a year and a 53 percent fall.

After a dramatic decline last month, the ARK Innovation ETF (ticker: ARKK) has steadied off - it's practically flat in February – but the headwinds surrounding its speculative growth picks are just becoming more vital. Many businesses that thrived during the pandemic are being hammered by the economic reopening, not only because yields are rising as investors prepare for the US Federal Reserve to raise interest rates, which is terrible news for unprofitable businesses, but also because the economic reopening is hammering many of the businesses that thrived during the pandemic.

Roku, Teladoc, and Zoom, all winners in the work-from-home era, have had their stock prices plummet by as much as 74% in the past year.

Short bets against ARK, according to IHS Markit data, hit a fresh high of 11.4 percent of outstanding shares this week. The Tuttle Capital Short Innovation ETF (SARK), which beats the ARK, now has assets worth more than $US300 million ($416 million).

"Those equities are supported by speculation, and speculation pays less well when the Fed raises rates," said Brent Schutte, chief investment strategist at Northwestern Mutual Wealth Management Co. "Much of what's happening in the market reminds me of what happened in the late 1990s when market segments were bid up to levels based on future assumptions."

Because its price chart resembles that of the Nasdaq index of technology businesses from more than two decades ago, analogies to that period and the dot-com implosion that followed are becoming more common in discussions of ARK.

"Today marks the 253rd trading day from ARK's all-time high," Jessica Rabe, co-founder of DataTrek Research, wrote in a Tuesday note, "while the Nasdaq was down 60% from its dot-com bubble top on the same day in 2001."

"If 2000/2001 analog holds, we should see ARK continuing to fall over the following three weeks. The Nasdaq dropped 18.7% in the next 16 trading days "recent."

Net flows are positive.

The better news for investors and Ms. Wood is that there may be some immediate respite. The Nasdaq rose 41% in six weeks in 2001 before falling.

The ARK Investment Management did not respond to a request for comment.

Most of ARK's $US15 billion asset loss has been attributed to bad performance, a plus for the company. Since the fund achieved an intraday high of $US159.70 a year ago this week, investors have withdrawn only around $US465 million, and ARK's net flows this year are positive despite a more than 20% drop.

This exceptional loyalty prevents a worsening situation and allows Wood's approach to recovering. The star fund manager has consistently emphasized that her funds have a five-year investment horizon and that she believes in many good options.

Mr. Schutte, on the other hand, says the drop is understandable because several of the company's biggest bets, such as Teladoc and Zoom, are becoming less significant as COVID-19 approaches.

"During the pandemic, there were a lot of questions about what would happen to society and how we'd go about our lives," he added.

"You drew in new investors who wanted to know "what are the upcoming themes I should invest in?" I believe you got a washout of it as well."

On Friday, Cathie Wood sold $148.9 million worth of Palantir stock, halving her exposure.

Ark Investment Management, run by Cathie Wood, sold more Palantir Technologies Inc PLTR -6.39 percent shares on Friday, cutting its stake in the Peter Thiel-backed company.

According to Friday's closing price, the famous investment management firm sold 13.5 million shares of the big data company, valued at $148.9 million.

Palantir's stock fell 6.4 percent to $11.02 per share on Friday. The stock has lost 16% of its value in the last week.

Before Friday's trade, Ark Invest held 25.53 million shares in Palantir, suggesting that the famous stock picker had trimmed over 52 percent of its total keeping a day later.

After the business disclosed lower-than-expected fourth-quarter earnings before the market opened on Thursday, Ark Invest, located in St. Petersburg, California, dumped shares in Palantir for the second time.

The software firm, well-known for its work with government organizations, posted earnings of 2 cents per share, falling short of the analyst consensus of 4 cents. The company recorded quarterly revenues of $432.87 million, higher than the $417.69 million predicted by analysts.

Palantir's stock had been sold for 4.77 million shares by the investment firm the day before.

All six of Ark Invest's active exchange-traded funds own Palantir stock, including the flagship Ark Innovation ETF ARKK -4.88 percent.

Before the recent sell-off, Ark Invest had been stockpiling Palantir shares for months.

Cathie Wood appeared on television to defend her ARK funds' dismal performance. It didn't go quite as planned.

The Ark Innovation ETF (ARKK), Cathie Wood's flagship fund, is down 30% year to date and more volatile than almost any other fund on the market. On CNBC's Halftime Report, Wood jumped at the chance to defend the fund and its deflated price, which is currently $68.80, down from $155 a year ago.

"We've seen a significant decline," Wood said, adding, "We feel innovation is at bargain basement zone." Even though her ETF was underperforming, she emphasized that her companies were still "very inexpensive" and that the current fund loss was temporary. When the call's 40 free minutes were finished, Zoom gave her an extra 10 minutes to complete the interview.

Having Zoom check to see whether she was "running out of time?" Wood, who has been aggressively buying up shares in Zoom and other IT firms that have fallen from their pandemic highs, was unhappy. Zoom, like Wood's other significant tech holdings, Teladoc Health, Roku, and Roblox, is down 20% to 40% year to date as investors worry about rising interest and inflation rates.

However, a significant chunk of the interview was devoted to a personal assault on Cathie Wood, who was named the most excellent stock picker in 2020 by Bloomberg's then-Editor-in-Chief Matthew Winkler after correctly forecasting that Tesla will one day be valued at more than $1 trillion.

Wood bluntly ignored Tuttle Capital Management's Short Innovation ETF (SARK), which tracks the inverse performance of ARKK using swaps contracts for the sole purpose of betting against Cathie Wood's selections. "They're not conducting any research." She explained, "All they're doing is shorting innovation."

Of course, SARK is betting against Cathie Woods, not on innovation. "Well, we stand for invention," Wood responded. The SARK ETF has gained 55 percent since its debut, whereas the ARKK ETF has declined by 42 percent.

Tuttle Capital Management CEO Matthew Tuttle chimed in on the SARK ETF, calling it a "tool" for investors. According to SARK, "to convey a negative view of the market, innovative enterprises, the current rising rate environment, or a [specific] portfolio manager if they wish." "It's un-American not to have options in the marketplace," Tuttle told Insider on Thursday.

In any event, Wood is making progress. Her main concern currently is bearish calls on her ETF. "Our major concern is that our investors convert temporary losses into long-term losses," Wood continued.